MedPharm, specialist in contract topical and transdermal pharmaceutical development, has announced the appointment of Simon Redgrove as Chairman of the Board and Dr Jeremy Drummond as VP of Business Development and member of the Executive Leadership Team.
The appointments come as MedPharm benefits from increased revenues as a result of integrating services with its fully functioning US laboratory facilities in North Carolina.
Simon Redgrove has built a strong reputation in the financial business community for nurturing the growth of businesses. He will provide overall guidance to the board and brings a depth of knowledge of fostering companies like MedPharm through critical growth stages in development.
Redgrove said: “I am delighted to be joining the MedPharm board as Chairman. The company has a solid track record of growth during the last nineteen years. I am looking forward to helping MedPharm grow on the back of the many exciting innovations it is bring to its services to support customers’ development projects.”
Redgrove was a Founder and Managing Director of Cavanagh Group in 1996, which he took to the AIM market in 2001 and sold to Close Brothers in 2011. Subsequently as Head of Advice at Close Brothers Asset Management he was instrumental in turning around the business. In 2015 Simon cofounded MunnyPot, a low cost online investment service.
Dr Andy Muddle, CEO and Co-founder of MedPharm, said: “We are very pleased to have secured Simon Redgrave as our Chairman. We will look to use his different perspective and strong business acumen to ensure MedPharm continues to grow in line with its ambitious strategic plan.”
Dr Jeremy Drummond joins MedPharm having spent more than 20 years in roles of increasing responsibility leading the commercial supply of product and services to pharmaceutical companies across the globe. His role is to help clients understand how MedPharm can mitigate risk and shorten their development timelines of their generic or proprietary products.
Drummond said: “MedPharm has a fantastic reputation in the pharmaceutical development marketplace and is continuing to bring new ideas to help reduce the cost and reduce the time to market for our customers’ topical and transdermal development programmes. I look forward to helping the team expand these benefits to customers focused on ear, airway and eye indications where MedPharm has demonstrated it has much to offer.”
Drummond started his career as a formulation scientist at major multinationals and has a PhD in organic chemistry from the University of Cambridge.
Professor Marc Brown, MedPharm’s Chief Scientific Officer and Co-Founder, said: “Jeremy brings a wealth of experience to the Executive Team. His commercial experience and knowledge is strongly complimented by his technical background and we are looking forward to him driving forward MedPharm’s presence in the global pharmaceutical CRO marketplace.”
